Amneal Pharmaceuticals (AMRX) Earnings Date, Estimates & Call Transcripts $9.41 +0.08 (+0.86%) Closing price 04:00 PM EasternExtended Trading$9.05 -0.36 (-3.87%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Amneal Pharmaceuticals Earnings Summary Amneal Pharmaceuticals posted Q2 2025 earnings on August 5, 2025, reporting an EPS of $0.23, which beat analysts' consensus estimates of $0.17 by $0.06. With a trailing EPS of $0.01 and a P/E Ratio of 941.94, Amneal Pharmaceuticals' earnings are expected to grow 13.21% next year, from $0.53 to $0.60 per share. Consensus EPS (Aug. 5) $0.17 Actual EPS (Aug. 5) $0.23 Beat By $0.06 Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Slide Deck Quarterly Report (10-Q)Slide DeckFull Screen Slide DeckPowered by Get Amneal Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amneal Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataAMRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AMRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Amneal Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $0.53 EPSNext Year EPS Consensus Estimate $0.60 EPS Amneal Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025$0.17$0.23+$0.06$0.07--5/2/2025Q1 2025$0.14$0.19+$0.05$0.04$714.78M$695.42M2/28/2025Q4 2024$0.15$0.12 -$0.03-$0.10$708.21M$730.52M8/9/2024Q2 2024$0.11$0.15+$0.04$0.28$657.43M$701.78M5/3/2024Q1 2024$0.08$0.12+$0.04$0.54$623.08M$659.19M3/1/2024Q4 2023$0.05$0.12+$0.07$0.64$630.67M$616.98M11/7/2023Q3 2023$0.10$0.17+$0.07$0.28$613.74M$620.04M Amneal Pharmaceuticals Earnings - Frequently Asked Questions When did Amneal Pharmaceuticals announce their last quarterly earnings? Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earning data on Tuesday, August 5, 2025. Learn more on AMRX's earnings history. What guidance has Amneal Pharmaceuticals issued on next quarter's earnings? Amneal Pharmaceuticals issued an update on its FY 2025 earnings guidance on Tuesday, August, 5th. The company provided EPS guidance of 0.700-0.750 for the period, compared to the consensus estimate of 0.705. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion. Did Amneal Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Amneal Pharmaceuticals (NASDAQ:AMRX) reported $0.23 earnings per share (EPS) to beat the analysts' consensus estimate of $0.17 by $0.06. Learn more on analysts' earnings estimate vs. AMRX's actual earnings. How can I listen to Amneal Pharmaceuticals' earnings conference call? The conference call for Amneal Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Amneal Pharmaceuticals' conference call transcript? The conference call transcript for Amneal Pharmaceuticals' latest earnings report can be read online. Read Transcript How much revenue does Amneal Pharmaceuticals generate each year? Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded annual revenue of $2.79 billion. How much profit does Amneal Pharmaceuticals generate each year? Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded net income of -$116.89 million. AMRX has generated $0.01 earnings per share over the last four quarters. What is Amneal Pharmaceuticals' price-to-earnings ratio? Amneal Pharmaceuticals (NASDAQ:AMRX) has a trailing price-to-earnings ratio of 940.44 and a forward price-to-earnings ratio of 17.71. What is Amneal Pharmaceuticals' EPS forecast for next year? Amneal Pharmaceuticals' earnings are expected to grow from $0.53 per share to $0.60 per share in the next year, which is a 13.21% increase. More Earnings Resources from MarketBeat Related Companies QIAGEN Earnings Moderna Earnings Verona Pharma PLC American Depositary Share Earnings BridgeBio Pharma Earnings Blueprint Medicines Earnings Elanco Animal Health Earnings Roivant Sciences Earnings Legend Biotech Earnings Revolution Medicines Earnings Rhythm Pharmaceuticals Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? This page (NASDAQ:AMRX) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access